American biopharmaceutical company with offices at King of Prussia in Pennsylvania and in Boston, founded in 1996 around tetracycline chemistry and taken private in 2023. Develops and sells omadacycline, an aminomethylcycline antibiotic marketed as Nuzyra for community acquired bacterial pneumonia and skin infections and studied in nontuberculous mycobacterial disease, works with United States government agencies on antibiotics for biodefence, and runs its own clinical development and medical affairs.
Aucun commentaire disponible.
Laissez votre note & commentaire